The Congress of the European Societies of Toxicology is organizing EuroTox 2025 to focus on this year's theme “Toxicology addresses Society’s real-life risks for sustainable health and well-being”. The 2025 program will focus on cutting-edge scientific breakthroughs and interdisciplinary collaboration. Emerging technologies and methodologies such as humanized liver applications in toxicology will be highlighted, while fostering discussions on public health safety and environmental sustainability.
PhoenixBio is excited to be sponsoring a booth and attending the EuroTox 2025 in person at the Megaron Concert Hall in Athens, Greece from September 14th - 17th, 2025. Meet with our team at Booth #A17 to learn more about PhoenixBio's capabilities and how we can help you advance and deliver tomorrow’s technologies.
While you're here, be sure to to speak with our team about fresh human hepatocytes or translation animal models. And be sure to check our relevant posters featuring PXB-mice such as the one highlighted below:
- Poster P04-10, September 15th, 2025
Title: Changes in miRNA levels as biomarkers for drug-induced liver injury in human plasma
Abstract: MicroRNAs (miRNAs) have emerged as clinical risk markers of drug-induced liver injury (DILI). We have previously reported changes in the expression of miRNAs under the administration of drugs with relatively high incidence rates of drug-induced liver injury (hTOX) and drugs with negligible risk (non-hTOX) using chimeric mice with highly humanized livers as markers for assessing the risk of DILI. In this study, we aimed to determine whether the target miRNAs showed similar changes in a clinical setting using residual blood samples obtained after therapeutic drug monitoring (TDM).
Background: We have previously analyzed changes in expression of miRNAs under the treatment of drugs with relatively higher rate of hepatotoxic incidents (hTOX) and those with negligible hepatotoxic incidents (non-hTOX) using chimeric mice with highly humanized liver. As a result, we identified miR-4306, miR-340, and miR-1237, which showed reproducible changes, as biomarkers for DILI.